CANTOS: Dousing the Fire Within to Reduce CVD

Dr O’Donoghue discusses preliminary results from the CANTOS trial of canakinumab, a unique anti-inflammatory agent which represents a new pathway for treating cardiovascular disease.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s